AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Rhinocort Aqua Versus Placebo and Fluticasone Propionate
Phase 3
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 750
- Registration Number
- NCT00641680
Adults With Moderate to Severe Asthma
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 900
- Registration Number
- NCT00642122
New Nasal Applicator / New Formulation - User Study
Phase 2
Completed
- Conditions
- Seasonal Allergic Rhinitis
- Interventions
- Drug: PlaceboDevice: Budesonide
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00641979
New Version Pulmicort Turbuhaler USA Adults
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 525
- Registration Number
- NCT00642187
Assess the Efficacy and Safety of Rhinocort Aqua
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 650
- Registration Number
- NCT00641693
New Version Pulmicort Turbuhaler USA Children
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 430
- Registration Number
- NCT00642161
Varicella Vaccination With Pulmicort
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 250
- Registration Number
- NCT00641446
A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis
- First Posted Date
- 2008-03-24
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1000
- Registration Number
- NCT00641602
Study Evaluating the Clinical Benefit of SEROQUEL XR in Subjects With Schizophrenia
Phase 3
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2012-06-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 331
- Registration Number
- NCT00640601
- Locations
- 🇰🇷
Research Site, Seoul, Korea, Korea, Republic of
Quetiapine Extended Release Depression Symptoms
Phase 3
Completed
- Conditions
- SchizophreniaDepression
- Interventions
- First Posted Date
- 2008-03-21
- Last Posted Date
- 2012-06-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 216
- Registration Number
- NCT00640562
- Locations
- 🇮🇹
Research Site, Roma, Italy
© Copyright 2025. All Rights Reserved by MedPath